Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose.
López-Marte P, Soto-González A, Ramos-Tollinchi L, Torres-Jorge S, Ferre M, Rodríguez-Martinó E, Torres EA, Sariol CA. López-Marte P, et al. Among authors: soto gonzalez a. Vaccines (Basel). 2022 Aug 11;10(8):1301. doi: 10.3390/vaccines10081301. Vaccines (Basel). 2022. PMID: 36016189 Free PMC article.
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.
Vázquez LA, Tofé-Povedano S, Bellido-Guerrero D, Botella-Serrano M, Soto-González A, Mezquita-Raya P, Delgado E, Fajardo-Montañana C, Morales-Portillo C, Causanilles A, Rubio-de Santos M, Romera I, Jódar-Gimeno E. Vázquez LA, et al. Among authors: soto gonzalez a. Diabetes Ther. 2024 May 9. doi: 10.1007/s13300-024-01587-6. Online ahead of print. Diabetes Ther. 2024. PMID: 38722495 Review.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Physical activity patterns in type 1 diabetes in Spain: The SED1 study.
Gómez-Peralta F, Menéndez E, Conde S, Conget I, Novials A; SED and SED1 study investigators. Gómez-Peralta F, et al. BMC Sports Sci Med Rehabil. 2023 Jul 26;15(1):92. doi: 10.1186/s13102-023-00695-3. BMC Sports Sci Med Rehabil. 2023. PMID: 37491278 Free PMC article.
Kanamycin treatment in the pre-symptomatic stage of a Drosophila PD model prevents the onset of non-motor alterations.
Molina-Mateo D, Valderrama BP, Zárate RV, Hidalgo S, Tamayo-Leiva J, Soto-González A, Guerra-Ayala S, Arriagada-Vera V, Oliva C, Diez B, Campusano JM. Molina-Mateo D, et al. Among authors: soto gonzalez a. Neuropharmacology. 2023 Sep 15;236:109573. doi: 10.1016/j.neuropharm.2023.109573. Epub 2023 May 15. Neuropharmacology. 2023. PMID: 37196855
Identifying advanced MAFLD in a cohort of T2DM and clinical features.
Sanchez-Bao AM, Soto-Gonzalez A, Delgado-Blanco M, Balboa-Barreiro V, Bellido D. Sanchez-Bao AM, et al. Among authors: soto gonzalez a. Front Endocrinol (Lausanne). 2023 Feb 22;14:1058995. doi: 10.3389/fendo.2023.1058995. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36909342 Free PMC article.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Solomon SD, et al. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027570 Free article. Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
37 results